Debate: Statins should be used in patients with heart failure
AUTOR(ES)
Kjekshus, John
FONTE
BioMed Central
RESUMO
Treatment to prevent progression of heart failure has been targeted to reverse the consequences of heart failure and to a lesser extent the cause – the atherosclerotic plaque itself. Less than 50% of patients with heart failure are treated with lipid intervention. Heart failure (New York Heart Association [NYHA] functional classes I and II) is associated with an increase in low-density lipoproteins (LDL) and triglycerides while high-density lipoproteins (HDL) is lowered. In NYHA class IV, cholesterol is reduced due to depressed production in the liver. Although lipoproteins, especially LDL and HDL, may have some protective effect in binding and neutralising endotoxins released from the intestine during terminal heart failure, observational studies in patients with heart failure strongly suggest that lipid modification with statins may reduce progression of heart failure as well as reducing heart failure mortality.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=64828Documentos Relacionados
- Debate: Should statin be used in patients with heart failure?
- Pro/con clinical debate: Hydroxyethylstarches should be avoided in septic patients
- Debate: Albumin administration should not be avoided
- Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
- Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
